UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): July 11, 2006

                           DUSA PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


                                                    
           NEW JERSEY                    0-19777                22-3103129
(State or other jurisdiction of      (Commission File          (IRS Employer
         incorporation)                  Number)          Identification Number)


                                 25 UPTON DRIVE
                         WILMINGTON, MASSACHUSETTS 01887
          (Address of principal executive offices, including ZIP code)

                                 (978) 657-7500
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Securities Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



ITEM 8.01 - OTHER EVENTS.

     DUSA Pharmaceuticals, Inc. ("DUSA") issued a press release on July 11,
2006, reporting that it has filed lawsuits against physicians in California,
Florida and Ohio, alleging infringement of patents exclusively licensed to DUSA
which cover use of DUSA's Levulan(R) brand of aminolevulinic acid (ALA).
Additionally, a suit has been filed against a chemical supplier of ALA in
Arizona. These suits are part of DUSA's ongoing campaign to protect its
intellectual property.

     Except for historical information, this report, including the exhibit,
contains certain forward-looking statements that involve known and unknown risk
and uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements relate to the Company's
intention to continue its campaign to protect its intellectual property and its
constituents. Furthermore, the factors that may cause differing results include
the uncertainties of litigation, sufficient funding, maintenance of its patent
portfolio and other risks identified in DUSA's SEC filings from time to time.

ITEM 9.01 - FINANCIAL STATEMENT AND EXHIBITS.



Item No.   Description
--------   -----------
        
99         Press Release, dated July 11, 2006




                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        DUSA PHARMACEUTICALS, INC.


                                        By: /s/ D. Geoffrey Shulman
                                            ------------------------------------
                                            D. Geoffrey Shulman, MD, FRCPC
                                            Chairman of the Board and
                                            Chief Executive Officer

Dated: July 11, 2006



                                  EXHIBIT INDEX



Item No.   Description
--------   -----------
        
99         Press Release, dated July 11, 2006